Ipamorelin and Tirzepatide Together: What Is Known
Ipamorelin and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
Side by side
Showing 10 of 13 fields where the two differ. PCAC vote, Jul 2026, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.
| Field | Ipamorelin | Tirzepatide |
|---|---|---|
| Class | GHRP (ghrelin receptor agonist) | GLP-1 / GIP dual agonist |
| Also called | ipa, ipam | tirz, tirze, Mounjaro, Zepbound |
| Category | Growth hormone | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Ipamorelin is named as a growth hormone secretagogue in S2.2.4, prohibited at all times. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: International journal of colorectal disease 2014, PMID 25331030 | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | 2 human (2 randomized or controlled) of 12 summarised | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Ipamorelin: selective GH release
In its characterisation paper, ipamorelin was called the first GHRP-receptor agonist whose selectivity for GH release resembles that of GHRH.[16]
In rats, ipamorelin dose-dependently increased longitudinal bone growth.[17]
Tirzepatide: durability after lifestyle intervention
In SURMOUNT-3, tirzepatide produced -18.4% weight change against +2.5% with placebo after an intensive lifestyle intervention.[18]
In the Zepbound label, a reduced dose of insulin or an insulin secretagogue is noted as something that may be necessary when used with tirzepatide.[19]
Thyroid warning
The tirzepatide label warns that treatment-duration-dependent thyroid C-cell tumours occurred in rats.[19]
More ipamorelin animal data
In rats, ipamorelin and GHRP-6 increased bone mineral content versus vehicle.[20]
Together
The ipamorelin with tirzepatide search returned 1 PubMed record, and it is not classed as a study of the pair.
Calculated from pubmed query (ipamorelin[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); search date 2026-10-02; records returned 1; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key ipamorelin__tirzepatide); no arithmetic applied.
WADA's list names ipamorelin as a growth hormone secretagogue.[4]
Common questions
Can you take ipamorelin with tirzepatide?
The PubMed search and cited studies include no trial of the two together. The human ipamorelin trial cited was in a postoperative bowel setting.[8]
Ipamorelin vs tirzepatide: what is each studied for?
Ipamorelin evidence is rat bone data and a post-surgery bowel trial, whereas tirzepatide has randomized weight-loss trials.[18]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 6Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 7Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 8Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 9The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
- 10These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 11Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 12Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 13Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 14PubMed search: (ipamorelin[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 16Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
- 17Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1999PMID 10373343Accessed 2 Oct 2026
- 18Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.Nature medicine · 2023PMID 37840095Accessed 2 Oct 2026
- 19ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 20The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.The Journal of endocrinology · 2000PMID 10828840Accessed 2 Oct 2026
Found an error? Report a correction.